Igor Matushansky - 01 Feb 2022 Form 4 Insider Report for HOOKIPA Pharma Inc. (HOOK)

Reporting relationship: Chief Medical Officer
Issuer ticker: HOOK
Reported as of: 01 Feb 2022
Net transaction value: +$119,463
SEC form: 4
Accepted by SEC: 01 Feb 2022, 19:49:32 UTC
Prior SEC filing: 12 Jan 2022
Next SEC filing: 20 Apr 2022
Source filing: View source filing
Reporting owner signature: /s/ Reinhard Kandera, as Attorney-in-Fact

Key filing fact

Igor Matushansky filed Form 4 for HOOKIPA Pharma Inc. (HOOK) on 01 Feb 2022.

Key facts

This page summarizes Igor Matushansky's Form 4 filing for HOOKIPA Pharma Inc. (HOOK).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 01 Feb 2022, 19:49.

Change

Previous filing in this sequence was filed on 12 Jan 2022.
Current net transaction value: +$119,463.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HOOK transaction

Common Stock

Award

Transaction value: $44,799
Shares: +14,933
Change %: +18%
Price: $3.00
Shares after: 100,240
Date: 01 Feb 2022
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HOOK transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $74,664
Shares: +24,888
Change %
Price: $3.00
Shares after: 24,888
Date: 01 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 24,888
Exercise price: $1.50
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Reporting Person was awarded 14,933 unrestricted shares of common stock as a portion of their base salary for the six month ending June 30, 2022.

Footnote F2

This stock option is fully vested.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .